Stockpolly
Search
BMEA · NASDAQ · Biotechnology

Biomea Fusion (BMEA)

Develops oral small-molecule medicines for diabetes and obesity.

$1.92
Pre-market−0.02 (−0.78%)
At close$1.94(+7.50%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000010000
Gross profit0000000−10000
313741393430302121121313
Research & development253134322725231714899
667775754444
General & administrative667775754444
Other expenses000000002000
Operating income−31−37−41−39−34−30−30−21−21−12−13−13
3222110141604
Interest income322211014−400
Other non-operating income0−2−2−2−1−10−1−2−160−4
Income before tax−28−35−39−37−33−29−29−21−165−12−8
Net income from continuing operations−28−35−39−37−33−29−29−21−165−12−8
Net income−28−35−39−37−33−29−29−21−165−12−8
EPS, basic−$0.80−$0.98−$1.09−$1.03−$0.91−$0.81−$0.80−$0.51−$0.27$0.06−$0.17−$0.12
EPS, diluted−$0.80−$0.98−$1.09−$1.03−$0.91−$0.81−$0.80−$0.51−$0.27$0.06−$0.17−$0.12
Weighted average shares, basic363636363636374141727272
Weighted average shares, diluted363636363636374141727272
EBITDA−31−34−39−37−32−29−29−20−185−12−8
Depreciation & amortization000000010000
EBIT−31−35−39−37−33−29−29−21−195−12−8